AB
CRVS icon

Amalgamated Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Amalgamated Bank’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,799
Closed -$14K – 1908
2025
Q4 		$14K Buy
1,799
+10
+0.6% +$79 ﹤0.01% 2271
2025
Q3 		$13K Hold
1,789
– – ﹤0.01% 2331
2025
Q2 		$7K Buy
+1,789
New +$6.51K ﹤0.01% 2578

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amalgamated Bank's CRVS Position: Q1 2026 in Review

Amalgamated Bank sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 1,799 shares — an estimated $14K sold.

Amalgamated Bank first reported a position in CRVS in Q2 2025 and held it in 3 quarters. The position peaked at $14K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Amalgamated Bank reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,799 Corvus Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Amalgamated Bank first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Corvus Pharmaceuticals position peaked at $14K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.